Open an account

Statera Biopharma

STAB · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.0001

About STAB

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The firm has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. The company has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Employees
46
Headquarters
Fort Collins, Delaware
Listed
Jul 21, 2006
Sector
Health Care
Industry
Biotechnology
Website
staterabiopharma.com

STAB key statistics

Market cap
7.14K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.25K
Volume
6.02K
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0266
52 Week low
$0.00

Statera Biopharma (STAB) at a glance

As of Oct 20, 2026, Statera Biopharma (STAB) shares are priced at $0.0001, giving the company a market cap of 7.14K and a price-to-earnings ratio of 0.00.

Volume so far is 6.02K shares, in line with the average of 6.25K shares a day.

Over the past year Statera Biopharma has ranged from $0.00 to $0.0266, and now sits 0% of the way up that range.

Statera Biopharma met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY14 it reported -$0.60 per share against an estimate of -$1.02.

STAB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 71.2% on average.

  1. Q1 FY12: reported -$3.00 per share against an estimate of -$2.96
  2. Q2 FY12: reported -$2.80 per share against an estimate of -$0.816
  3. Q4 FY12: reported $1.40 per share against an estimate of -$4.28
  4. Q1 FY13: reported -$4.40 per share against an estimate of -$3.47
  5. Q2 FY13: reported -$1.40 per share against an estimate of -$3.16
  6. Q3 FY13: reported -$1.80 per share against an estimate of -$2.75
  7. Q4 FY13: reported -$0.20 per share against an estimate of -$2.45
  8. Q1 FY14: reported -$0.60 per share against an estimate of -$1.02

STAB news

  • Press releaseBusiness Wire

    Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

Similar companies

Companies in the same industry as Statera Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.